Condition: Neuroendocrine Tumors Unresectable · Neuroendocrine Tumor Metastatic · Gastroenteropancreatic Neuroendocrine Tumor · Sponsor: Perspective Therapeutics
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
This description comes directly from the study's public registry record.
ClinicalTrials at Perspectivetherapeutics · (206) 676-0900 · clinicaltrials@perspectivetherapeutics.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Biogenix Molecular | Miami, Florida, United States | Recruiting |
| The University of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| BAMF Health | Grand Rapids, Michigan, United States | Recruiting |
| Michigan Health Professionals | Troy, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05636618